PetCaseFinder

Peer-reviewed veterinary case report

Early blood tests predict treatment success in cats with effusive FIP

By Takano, Tomomi et al.·Published in Journal of feline medicine and surgery·2026·School of Veterinary Medicine, Japan·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Early blood RNA clearance and protein fraction profiles predict treatment outcomes in cats with effusive feline infectious peritonitis.

Species:
cat

Plain-English summary

A group of 15 cats diagnosed with effusive feline infectious peritonitis (FIP) were treated with antiviral medications like GS-441524 and remdesivir to see how their blood tests could predict treatment success. Cats that responded well to treatment had lower levels of viral RNA in their blood and different protein profiles compared to those that did not respond. Specifically, higher levels of certain proteins and lower viral loads were linked to better outcomes. This study suggests that monitoring these blood markers can help veterinarians make better treatment decisions for cats with FIP.

People also search for: cat FIP treatment success · feline infectious peritonitis symptoms · antiviral treatment for cat FIP

Abstract

ObjectivesThe present study retrospectively examined effusive feline infectious peritonitis (FIP) cases to investigate whether baseline viral RNA loads and serum biomarkers are associated with treatment responses and to identify early prognostic indicators that will guide clinical decision-making.MethodsA total of 15 cats with effusive FIP that presented to a primary care veterinary hospital in Japan between August 2024 and August 2025 were included. The diagnosis was based on the European Advisory Board on Cat Diseases guidelines, combining clinical presentation, laboratory findings and feline coronavirus (FCoV) RNA detection by RT-qPCR. Antiviral treatment included GS-441524, remdesivir, molnupiravir or adjunctive nirmatrelvir. Cats were retrospectively classified as high-responders (HRs), low-responders (LRs) or non-responders (NRs), based on the blood FCoVgene RNA load 2 weeks after treatment initiation. LR and NR cats were combined (LR/NR, n&#x2009;=&#x2009;10) in analyses. Viral RNA loads in ascitic fluid and blood, routine haematology, acute-phase proteins and serum protein fractions were compared between groups.ResultsAt treatment initiation, the LR/NR group had significantly higher bloodgene RNA loads (<0.01) and ascitic fluid RNA loads (<0.05) than the HR group. In contrast, no intergroup differences were detected ingene loads. Routine haematological markers revealed higher total protein, globulin (Glb) and lactate dehydrogenase in the LR/NR group, and no significant differences in albumin (Alb), total bilirubin or serum amyloid A. A serum protein fraction analysis showed distinct profiles: the HR group had higher albumin:globulin ratios and higher Alb, alpha (&#x3b1;)1-, &#x3b1;2- and beta-Glb fractions, while the LR/NR group had a markedly higher gamma (&#x3b3;)-Glb fraction. The persistence of blood viral RNA 2 weeks after treatment initiation, together with opposing changes in the &#x3b1;2- and &#x3b3;-Glb fractions, emerged as promising predictors of treatment outcomes.Conclusions and relevanceBaseline bloodgene RNA loads and serum Glb fractions have potential as early prognostic indicators of therapeutic responses in effusive FIP. Some of these results support the utility of combining viral and host biomarkers to improve outcome predictions and treatment monitoring.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41294213/